Syneos Health Signs New Service Agreement With Pfizer
July 13 2020 - 8:30AM
Syneos Health® (Nasdaq:SYNH), the only fully integrated
biopharmaceutical solutions organization, today announced that it
has signed a new three-year agreement with Pfizer Inc. (NYSE: PFE)
to deliver global product development solutions to support Pfizer's
portfolio. Under the terms of the agreement, Pfizer has the right
to extend the term for up to an additional two years. Financial
details of the agreement were not disclosed.
This agreement builds on a longstanding relationship where
Syneos Health has provided insights and expertise across the
Clinical and Commercial continuum to support product development.
The Company will continue to deliver a broad range of capabilities
customized to meet Pfizer’s goals across its portfolio, including
full service and FSP solutions.
“Our ability to deliver deep therapeutic expertise, while
bringing forward insights that can facilitate shorter and more
efficient trials, has proven to be advantageous in our work with
Pfizer,” said Paul Colvin, President, Syneos Health Clinical
Solutions. “This new agreement allows us to continue our
collaboration to deliver flexible and innovative solutions. We are
pleased to expand our Pfizer relationship to optimize their
portfolio and deliver on our shared purpose to change patients’
lives.”
About Syneos Health Syneos Health (Nasdaq:SYNH)
is the only fully integrated biopharmaceutical solutions
organization. Our company, including a Contract Research
Organization (CRO) and Contract Commercial Organization (CCO), is
purpose-built to accelerate customer performance to address modern
market realities. Created through the merger of two
industry-leading companies – INC Research and inVentiv Health – we
bring together approximately 24,000 clinical and commercial minds
with the ability to support customers in more than 110 countries.
Together we share insights, use the latest technologies and apply
advanced business practices to speed our customers’ delivery of
important therapies to patients. To learn more about how we are
shortening the distance from lab to
life® visit syneoshealth.com.
Syneos
Health Investor Relations Contact: |
|
Syneos
Health Press/Media Contact: |
Ronnie Speight |
|
Danielle DeForge |
Senior Vice President, Investor Relations |
|
Executive Director, External Communications |
+1 919 745 2745 |
|
+1 202 210 5992 |
Investor.Relations@syneoshealth.com |
|
danielle.deforge@syneoshealth.com |
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jul 2023 to Jul 2024